safety data in phase ii juliet trial in dlbcl
Published 5 years ago • 86 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
3:08
response data from the juliet trial in dlbcl
-
5:51
updated juliet results for tisagenlecleucel in dlbcl
-
0:43
safety findings for axi-cel in patients with dlbcl
-
10:23
data from the juliet trial of ctl019 for relapsed or refractory diffuse large b-cell lymphoma
-
0:55
tisagenlecleucel in r/r follicular lymphoma: elara data
-
1:17
dr. borchmann discusses the updated analysis of juliet in dlbcl
-
3:46
juliet trial update: myc expression and t-cell responses in r/r dlbcl
-
5:51
latest results from juliet: tisagenlecleucel in adults with dlbcl
-
56:44
treatment innovation in dlbcl: real-world insight on integrating antibodies and cellular therapy
-
7:35
long term data from juliet trial, using tisagenlecleucel for patients with relapsed or treatment...
-
22:26
key novel agents for relapsed diffuse large b-cell lymphoma
-
27:20
cd19-targeting in relapsed/refractory dlbcl: optimizing the use of noncellular therapies
-
1:20:47
practice-changing data in relapsed/refractory diffuse large b-cell lymphoma
-
1:09
car t-cell therapy offers hope in dlbcl
-
5:01
portia: tisagenlecleucel and pembrolizumab in r/r dlbcl
-
3:23
the phase ii ezh2 inhibitor trial
-
3:26
lymphodepletion for car t-cell therapies in dlbcl
-
3:51
long-term outcomes on tisagenlecleucel: 4 years in dlbcl and fl
-
8:50
an update of car t-cell therapies in lymphoma